NCT00537225

Brief Summary

Patients with peripheral arterial disease (PAD) experience significant functional limitations due to ischemic symptoms (claudication) and are at high risk for CVD morbidity and mortality resulting from untreated cardiovascular disease (CVD) risk factors and aggressive atherosclerosis. The overall Goal of this randomized controlled clinical trial is to examine the synergistic effect of a multifactor risk reduction on walking distance, blood flow and quality of life in 300 patients with PAD. Specifically, we will compare the effects of 24 months of a novel, yet well-tested multiple risk factor reduction program, the Health Education and Risk Reduction Training (HEAR2T) Program for PAD versus enhanced standard care on: 1) symptom limited walking distance as assessed by treadmill exercise testing and walking impairment questionnaire; 2) endothelial function as measured by flow mediated vasodilation (FMVD) via brachial artery ultrasound. We will also explore the association between FMVD and decreased oxidative stress (as measured by oxygen radical absorbance capacity and urinary isoprostanes) and reduced degradation of nitric oxide (NO) and/or increased NO biosynthesis (as measured by urine nitrogen oxide, plasma nitrogen oxide, plasma asymmetric dimethylarginine, plasma, urine and platelet cyclic GMP). Secondary hypotheses examine the association between reducing CVD risk factors, improved endothelial function, increased walking distance, improved quality of life and number of metabolic syndrome abnormalities in PAD patients. Significance. This study will contribute to evidence on the efficacy of multiple risk factor reduction on improving physical function and quality of life in the understudied, elderly PAD patient. This study will also provide preliminary evidence for the biological basis for the efficacy of multifactor risk reduction in restoring vascular homeostasis, critical because of its role in antiatherogenesis and maintaining vasoreactivity, both necessary for slowing the progression of atherosclerosis.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
300

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Sep 2006

Longer than P75 for not_applicable

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2006

Completed
1.1 years until next milestone

First Submitted

Initial submission to the registry

September 27, 2007

Completed
4 days until next milestone

First Posted

Study publicly available on registry

October 1, 2007

Completed
5.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2013

Completed
Last Updated

April 19, 2023

Status Verified

April 1, 2023

Enrollment Period

6.8 years

First QC Date

September 27, 2007

Last Update Submit

April 17, 2023

Conditions

Keywords

peripheral arterial diseasewalking timelifestyle modificationcardiovascular risk reductionexercisedietclaudication

Outcome Measures

Primary Outcomes (1)

  • walking time

    determined by symptom limited walking time on treadmill exercise test

    24 months

Secondary Outcomes (1)

  • quality of life, biomarkers of CVD risk, endothelial function

    24 months

Study Arms (2)

A-Exercise group

EXPERIMENTAL

Home based exercise

Behavioral: exercise

B- Usual Care

NO INTERVENTION

Exercise as usually prescribed by provider

Interventions

exerciseBEHAVIORAL

tailored multifactor CVD risk reduction

A-Exercise group

Eligibility Criteria

Age50 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subjects eligible for this study include:
  • Age 50 years or older with one or more CVD risk factor
  • PAD secondary to atherosclerosis with significant claudication
  • Claudication is defined as pain, ache, cramp, numbness or severe fatigue of muscles of one or both lower extremities, reproducibly provoked by walking causing the patient to slow or stop walking pace
  • Ankle-brachial index (ABI) \< 0.90
  • In diabetics ABI is inaccurate, in which case, we will substitute toe pressures \< 60 mmHg
  • ABI one minute after exercise is at least 20% lower than index leg resting ABI
  • Capable of walking at least 50 feet
  • Primary limitation to walking is claudication, not coexisting conditions such as severe CAD, uncontrolled hypertension, pulmonary disease, severe arthritis, or orthopedic conditions
  • Difference of walking time between two consecutive (of four) baseline treadmill tests must be \< 25%.

You may not qualify if:

  • Active malignancy or tumor or other condition that would severely limit life expectancy
  • Any type of major surgery during the last 3 months (i.e. aortic or lower extremity arterial surgery, angioplasty, or lumbar sympathectomy, leg amputation above the ankle)
  • Residence in a long-term institutional setting
  • Psychiatric disorders with currently active manifestations
  • Uncontrolled metabolic disorders (renal failure, liver failure, thyrotoxicosis)
  • Active symptoms suggestive of an acute coronary syndrome or decompensated heart failure
  • Lack of phone access (either by self or through neighbors/family members)
  • Other specified circumstances incompatible with case-management (i.e., plan to move away from area)
  • Presence of another household member or first-degree relative already enrolled in the study
  • Current enrollment in another clinical trial
  • Regular participation in an exercise program for at least 3 months prior to study entry.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (2)

  • Oka RK, Conte MS, Owens CD, Rapp J, Fung G, Alley HF, Giacomini JC, Myers J, Mohler ER 3rd. Efficacy of optimal long-term management of multiple cardiovascular risk factors (CVD) on walking and quality of life in patients with peripheral artery disease (PAD): protocol for randomized controlled trial. Vasc Med. 2012 Feb;17(1):17-28. doi: 10.1177/1358863X11430886.

    PMID: 22363015BACKGROUND
  • Oka RK, Alley HF. Differences in nutrition status by body mass index in patients with peripheral artery disease. J Vasc Nurs. 2012 Sep;30(3):77-87. doi: 10.1016/j.jvn.2012.04.003.

MeSH Terms

Conditions

Peripheral Arterial DiseaseMotor ActivityIntermittent Claudication

Interventions

Exercise

Condition Hierarchy (Ancestors)

AtherosclerosisArteriosclerosisArterial Occlusive DiseasesVascular DiseasesCardiovascular DiseasesPeripheral Vascular DiseasesBehaviorSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Motor ActivityMovementMusculoskeletal Physiological PhenomenaMusculoskeletal and Neural Physiological Phenomena

Study Officials

  • Roberta K Oka, ANP, DNSc

    PAIRE

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Home-based exercise
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 27, 2007

First Posted

October 1, 2007

Study Start

September 1, 2006

Primary Completion

June 1, 2013

Study Completion

June 1, 2013

Last Updated

April 19, 2023

Record last verified: 2023-04

Data Sharing

IPD Sharing
Will not share